A poor outlook capped a series of mishaps for generic drugs giant
A poor outlook capped a series of mishaps for generic drugs giant
The first biosimilars hit the U.S. in 2015.
The first biosimilars hit the U.S. in 2015.
A sign of the times.
A sign of the times.
Meet Lannett, the 73-year-old generic drugmaker.
Meet Lannett, the 73-year-old generic drugmaker.
Developing countries like China, Brazil and India will drive nearly half of...
Developing countries like China, Brazil and India will drive nearly half of the growth in drug spending in the near future. Here's how Big Pharma could play the trend.
Jerusalem-based Teva is said to be close to an agreement to acquire Dublin-...
Jerusalem-based Teva is said to be close to an agreement to acquire Dublin-based Allergan's generic drugs unit for between $40 billion and $45 billion.
Deal-hungry generics specialist bulks up with an offer sauced by debt and n...
Deal-hungry generics specialist bulks up with an offer sauced by debt and new shares.
